• Certara partnered with NVIDIA to advance its open integrated AI platform for drug discovery and development.
• The platform will integrate NVIDIA BioNeMo Agent Toolkit as an agentic framework alongside Certara’s scientific software, regulatory expertise, and proprietary datasets.
• Specialized AI agents will support biosimulation and evidence generation across development, including dosing strategy optimization, clinical data analysis, and trial simulations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Certara Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070800PRIMZONEFULLFEED9757920) on July 07, 2026, and is solely responsible for the information contained therein.